🔎 Trials Near Me

Utama › Karsinoma Sel Skuamosa Kepala dan Leher › Utah › Salt Lake City

Kajian klinikal Karsinoma Sel Skuamosa Kepala dan Leher di Salt Lake City, UT

11 kajian untuk Karsinoma Sel Skuamosa Kepala dan Leher sedang mencari peserta di lokasi dalam dan sekitar Salt Lake City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Mengambil pesertaFasa 3
  • University of Utah Sugarhouse Health Center, Salt Lake City
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
  • Farmington Health Center, Farmington · 15 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06992427

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Mengambil pesertaFasa 1
  • University of Utah - Huntsman Cancer Institute, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Mengambil pesertaFasa 3
  • Huntsman Cancer Institute, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07276399

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

Mengambil pesertaFasa 1/2
  • University of Utah Huntsman Cancer Institute, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06385080

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Mengambil pesertaFasa 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Mengambil pesertaFasa 1/2
  • University of Utah - Huntsman Cancer Institute, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05267626

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Mengambil pesertaKajian pemerhatian
  • Utah Cancer Specialists, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Mengambil pesertaFasa 1/2
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06330064

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • Utah Cancer Specialists, Salt Lake City
  • University of Utah Health Huntsman Cancer Hospital, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT03526835

Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.

Mengambil pesertaFasa 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Feb 2026 · NCT07044635

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Mengambil pesertaFasa 1/2
  • Utah Cancer Specialists (site 203), Salt Lake City
Umur 18 hingga 80 · Semua jantina · Dikemas kini 11 Dis 2025 · NCT03556228

Kajian Karsinoma Sel Skuamosa Kepala dan Leher di bandar lain

Kajian lain di Salt Lake City

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.